Hyperthermia Blog

News and Opinions About Our Industry

Last month the local affiliate in Salt Lake City, UT (headquarters for Pyrexar Medical) aired a five-part series on the use of hyperthermia in the treatment of cancer. The report focused on one of our customer sites, Gamma West Cancer Services, and their use of interstitial hyperthermia in combination with brachytherapy.

Key points from this series

  • Hyperthermia is a safe and highly effective cancer treatment
  • Several patients featured in the story had no expectation of survival before hyperthermia
  • Excellent adjunct treatment for Brachytherapy with similar treatment planning
 

We have added English language captions to the video series. This is an excellent opportunity to share this life-saving information on your social media websites. The more individuals that learn about this treatment, the more lives we can change.

Visit the Pyrexar Medical YouTube Channel or use the links below.

Part 5 of the ABC news series on hyperthermia is probably the most important.  In the past, we have talked about phase III clinical studies, and have shown peer-reviewed evidence that adding hyperthermia to radiotherapy and chemotherapy improves outcomes and extends life. We know it energizes the bodies immune system to fight the cancer on its own.  We know it is well excepted as a cancer treatment in Europe and Asia.

But none of that matters. No matter how effective hyperthermia treatment is, it will not save your mother, your father, sister, brother, aunt, uncle, grandmother, grandfather or your child, if it remains relatively unknown in the U.S.  Whether you know it or not, you have a choice in your medical treatment.  It takes research and advocacy and the sharing of information. In this news series, you met four people who are here today because someone advocated for them and for hyperthermia.

You can help more people survive cancer. Share this story. Shed some light that there are hyperthermia treatment protocols for most cancers that have solid tumors. Tell people that hyperthermia was once an ancient medical treatment, or that it uses some of the most advanced image-guided technology in medicine. Tell them there are 30 years of scientifically proven evidence, it has FDA approval, its available in university hospitals and cancer centers in this country and can be covered by insurance.  Tell them there is a map that will show them where the closest center is located. It is that simple.

why abc part 5 2018 key

See the video and full transcript at www.Good4Utah.com

Thank you to all of the generous individuals that were involved in making this story happen.  Thank you to the ABC Good4Utah news team for taking on topics that help others.  To Gamma West Cancer Services for not backing away from patients that others have given up on.  And to my co-workers at Pyrexar Medical, particularly Paul Turner, who continues to improve this technology, and has for over 40 years. Thank you.

See the complete ABC News series Part 1Part 2Part 3Part 4Part 5

 

Pyrexar is working very hard to bring innovation to our products.  But nothing is more important than sharing the message of hope that hyperthermia treatment can bring to cancer patients.  Although there is a long, successful history of this therapy, few Americans know about it.  We want to know why? 

Although hyperthermia system sales have been accelerating in the last two years in Asia, Europeans have had a long history of using this technology. In part 4 we meet Professor Dr. Peter Wust of Charité Universitätsmedizin Berlin who has been treating patients with hyperthermia for over three decades. The team at Charité are the world's leading experts in this type of cancer treatment.  You can learn more about the treatment options at the Charité in their patient brochure.

pyrexar abc part 4 2018 key

See the video and full transcript at www.Good4Utah.com

Charité Universitätsmedizin Berlin, currently uses the BSD-2000 3D Deep Regional system to deliver hyperthermia at any depth of the body.

See the complete ABC News series Part 1Part 2Part 3Part 4Part 5

 

In Part 3 of the hyperthermia news report, produced by Salt Lake City's ABC station Good4Utah, we meet Randy.  Randy is a great example of what hyperthermia could do for cancer patients around the world.  Randy was diagnosed with rectal cancer that had metastasized to his colon and lungs. The tumor was too large to be surgically removed. As in most cases with cancers this advanced, the doctor's tried to make the patient comfortable with pain killers and recommended hospice care.  I cannot imagine what that must feel like to hear that your life is at its end.

But Randy had an advocate in his sister and, through an internet search, found Dr. Hayes of Gamma West Cancer Services.  Dr. Hayes had a plan, treat the primary tumor with brachytherapy and hyperthermia to provided the best outcome.  Not only did the treatment shrink the primary tumor and kill the cancer, but also the other tumors continue to shrink or have completely disappeared. Randy has a new lease on life.

rectal cancer abc part 3 2018 key

I want to repeat this point. The primary tumor was treated with brachytherapy radiation and interstitial hyperthermia.  The metastatic sites of the colon and lung received no treatment, no radiation, and no chemotherapy.  How did the other cancers disappear? Immune Modulation.  Hyperthermia restarted the immune systems ability to recognize the cancer.  Any stray cancer cells that may find a new stronghold in the body were attacked by the body's own immune system.

When I have asked other doctors why hyperthermia is not used in all cancer treatment, the response I get is radiation and chemotherapy work "pretty well".  Our hope is hyperthermia will play more of a role in first line treatment as a non-pharmaceutical radiosensitizer (with little to no toxicity).

The patient was treated at Gamma West Cancer Services using brachytherapy and the Pyrexar BSD-500 Interstitial Hyperthermia System. See the video and full transcript at www.Good4Utah.com

See the complete ABC News series Part 1Part 2Part 3Part 4Part 5

 

Part 2 of the ABC News series visits two patients with life threatening recurrent cancers.  In this installment, we meet Jack, an avid race car driver whose prostate cancer returned after treatment two years ago.  Jack understands the devastating effects of cancer, he lost four siblings to the disease. Jack approached his cancer treatment like he approached racing, he planned to win. Jack is a winner, thanks to his willingness to seek out the best treatment solution, even though far away from home.

Meet Nicole, faced with the recurrence of an aggressive head/neck cancer.  One solution was to remove her tongue to save her life. Luckily she found Dr. Hayes who offered a different solution. Using brachytherapy and hyperthermia, Nicole kept her tongue and her ability to speak and swallow normally. Both patients are now one year cancer free.

tongue cancer abc part 2 2018 key

Both cases were treated at Gamma West Cancer Services using brachytherapy and the Pyrexar BSD-500 Interstitial Hyperthermia System. See the video and full transcript at www.Good4Utah.com

See the complete ABC News series Part 1Part 2Part 3Part 4Part 5

 

The ABC affiliate in Salt Lake City, Utah has produced a five-part series on the resurgence of hyperthermia in the treatment of cancer.  Part 1 of 5 aired this evening and features the Pyrexar BSD-500 Interstitial Hyperthermia System used as an adjunct to brachytherapy in the treatment of advanced recurrent prostate cancer.  Reporter Surae Chinn - @suraechinn asks Dr. Hayes of Gamma West Cancer Services to explain how he and his team use hyperthermia to improve cancer outcomes. See the video and full transcript at www.Good4Utah.com

hayes abc part 1 key 2018

As you may know, recurrent cancer is a challenge as the indication often proves to be radio-resistant.  With this in mind, Dr. Hayes has accepted patients that many have given up on.  It is his experience that adding hyperthermia at therapeutic temperatures for one hour will increase oxygenation, increase blood flow and perfusion, inhibit DNA repair and stimulate the body's immune response, making his treatment more effective than other oncologists in the area. Gamma West is able to provide interstitial radiotherapy (brachytherapy) followed quickly by interstitial hyperthermia, in as few as two treatments in a single day.

It is important to share these stories as hyperthermia has proven to change lives and extend life.

See the complete ABC News series Part 1Part 2Part 3Part 4Part 5

We just returned from Taiwan after attending the TASTRO -  Taiwan Society for Therapeutic Radiology and Oncology annual conference.  The event was held at the Tiangong Hall in the Kaohsiung Junhong Hotel in  Kaohsiung City. Presenters at the two day conference covered a range of topics including the Best of ASTRO topics (Head and Neck Cancer, Abdomen/Pelvis, Chest).  We also enjoyed the presentation on the use of brachytherapy in early stage breast cancer. We believe that interstitial hyperthermia, and the immune response trigger of heat, can play an important role in this treatment protocol. But the main focus of the event centered around proton therapy.

Dr. Zeljko Vujaskovic presented "Thermal Therapy in Cancer Treatment" as the keynote speaker of the event.

Univ. of Maryland Featured Speaker
Taiwan Society for Therapeutic Radiation Oncology Annual Conference
Ames Medical Represents Pyrexar

Our sales agent for Taiwan, Ames Medical, put together an excellent booth presentation for the Pyrexar product line

previous arrow
next arrow
Slider

The highlight of the conference was a keynote presentation by Dr. Zeljko Vujaskovic from the University of Maryland Proton Center. Dr. Vujaskovic provided an overview of the development of Thermal Therapy, with an emphasis on its reemerging role in cancer treatment.   Dr. Vujaskovic and his team have developed the world's first center to combine proton therapy and  thermal therapy treatment in a single facility. The team has recently started treating patients in the new thermal suite and early results are positive.  The University of Maryland has used the BSD-500 for many years and the recent addition of a BSD-2000 last spring will allow them to treat cases using hyperthermia in the superficial, interstitial, and deep regional modes.

AmesLOGOA special thanks to our Taiwan sales organization AMES Medical. They did a tremendous job hosting our team and creating a comprehensive marketing and sales presentation in the conference booth.


Plus: AIRO - Italian Association of Radiotherapy Oncology

TemaSinergie 250pxWe were also represented this month at the AIRO by our distributor Tema Sinergia. The 28th Annual AIRO was held Nov. 2-4 at the Rimini Conference Center, Rimini, Italy. The event is co-located with the 31st National Congress AIRB and the 10th National AIRO Youth Congress.

AIRO 2018

Thank you to the Tema Sinergia team for their great work.

We just returned from the 60th Annual ASTRO in San Antonio, Texas and wanted to share our experience. First, it was a great show for Pyrexar. We had immediate traffic in the booth and for the first time we did not have to explain the benefits of hyperthermia as a drug-free radiosensitizer or hyperthermia’s role as an immune modulator. Second, the recent announcement from the University of Maryland Proton Center of its new BSD-2000 hyperthermia suite and the follow-up article in DotMED.com created an immediate draw to the booth.

previous arrow
next arrow
Slider
 
The theme of this year's booth centered squarely on the advances of image guided thermal therapy and the BSD-2000 3D/MR, shown in the featured booth graphic, with hands on access to the Sigma Eye/MR Applicator and the newly redesigned Sigma 30 for the BSD-2000 and BSD-2000 3D/MR. The Sigma 30 is a 30cm applicator designed for limbs (soft tissue sarcoma) and pediatric applications.

The crowds and the physical space was about 20% smaller this year.  The quality of the show still maintained its excellence as an important platform for scientific review and new product introductions. Many of the large radiation equipment manufacturers focused more on software than hardware.

Stopping by the booth were hyperthermia luminaries, Dr. Zeljko Vujaskovic from University of Maryland, Dr. Mark Hurwitz from Thomas Jefferson Sidney Kimmel Cancer Center and Dr. Niloy Datta, Kantonsspital Aarau, Switzerland. Dr. Datta presented a poster titled "Therapeutic Options for Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-analysis" at the new ASTRO Digital Poster Pavilion.

We would also like to thank our partners Sennewald Medizintechnik (Germany/Europe/Russia) for their participation in the booth.  As well as Orientech (China); Tema Sinergie (Italy); Hanbeam Technology (South Korea) and our newest partners Sukosol (Thailand) and HuaLong BioMed (Taiwan), for bringing in a constant flow of prospects from around the globe.

Next stop is the 2018 Taiwan Radiation Oncology Annual Symposium sponsored by TASTRO - Taiwan Society for Therapeutic Radiation Oncology, held in Kaohsiung City, Taiwan Nov. 10 - 11. Our Taiwan partner Ames Medical will have a booth and Dr. Zeljko Vujaskovic is a featured speaker presenting his work in hyperthermia and its role in proton therapy.

zjelko at umm

In an announcement this week, the University of Maryland's Proton Center has established the world's first combined Hyperthermia/Proton Beam therapy center. The therapy suite features the BSD-2000 Deep Regional Hyperthermia system as a complement to the center's 122,000 sq. ft., five bay, $270M, Varian ProBeam Proton system.

See Announcement: High-Precision Proton Therapy More Effective in Treating Certain Cancers When Combined with Thermal Therapy

Proton therapy is a precise form of radiation for the treatment of solid, localized tumors. Unlike X-ray (photon) technology, protons deliver a maximum radiation dose that stops at the tumor site. This enables our physicians to target the cancer cells with millimeter precision while sparing normal, healthy surrounding tissue in the rest of your body.

Hyperthermia, as an adjunct therapy, is expected to provide the same functionality as it would for traditional radiotherapy by increasing tumor oxygenation; boosting effective dose by 150%; preventing DNA repair to damaged cancer cells and by awakening the bodies immune system to the identify and destroy cancer.  The big difference is the belief that Hyperthermia + Proton = Carbon Ion as theorized in a paper Could hyperthermia with proton therapy mimic carbon ion therapy? by Dr. Niloy Datta.

This is an exciting advancement for hyperthermia to the forefront of cancer treatment.

More: Maryland Proton Treatment Center combines hyperthermia with proton therapy

 

IJOH DEC2014

BSD-2000 3D/MR Independent Quality Study

An independent quality assurance study of the five clinical BSD-2000-3D/MR systems has been published in the International Journal of Hyperthermia by H. Mulder et al.  The intent of the study was to validate the accuracy and consistency of the deep heating focus and electronic steering of this system. The study test results concluded, on these five separate systems, that “the Pyrexar Medical BSD2000-3D MR compatible applicator provides robust and reproducible heating.“ The study found that the heating characteristics were reproducible within a 95% confidence interval of 0.4˚C. Based on these evaluations, the applicator was approved for clinical use. This study further made it clear that these BSD-2000 systems provide deep selective heating focus to the center of the body equivalent phantom along with the electronic steering precision.

   • Applicator provides robust reproducible heating
   • 95% confidence interval of 0.4˚C
   • Selective heating focus with electronic steering precision
   • 5 MR-based Hyperthermia Systems already Installed

Why is this important?

1) It shows that our systems design and manufacturing is solid, even in the most sophisticated products; 2) When designing a multi-hospital, multi-country clinical study, there is hardware reliance; and 3) The research community continues to invest its time in system validation, necessary to maintain standards that industry should follow.

About the BSD-2000 3D/MR

Pyrexar Medical manufactures the most advanced hyperthermia treatment systems in the world. The model BSD-2000-3D/MR has the capability to focus radiated RF power to deep sites in the body with 3D electronic steering. A further unique advancement of this configuration is that it has been integrated with magnetic resonance imaging (MRI) which has been adapted to display non-invasive temperature change images during the elevated temperature treatments. This unique system provides image guided thermal therapy of deep tumors within the patient’s body.

This excellent quality assurance study is important to our goal of assuring high quality hyperthermia cancer treatments and to allow for results of clinical studies, at various centers around the world, to be combined in future clinical research.

Systematic quality assurance of the BSD2000-3D MR-compatible hyperthermia applicator performance using MR temperature imaging
Mulder HT1, Curto S1, Paulides MM1, Franckena M1, van Rhoon GC1
2018 Sep 11:1-9. doi: 10.1080/02656736.2018.1497209

Editors Note:  The International Journal of Hyperthermia is the official journal of STM Society of Thermal Medicine, Japanese STM and ESHO European Society for Hyperthermic Oncology.  As of June 2018, IHJ has become a full Open Access Journal.

 

We have made some updates to the Pyrexar Medical website, both in style and performance. Our goal is to promote hyperthermia as a premier adjunct cancer treatment, and to make valuable clinical data and product information readily available.

New features include:

  • A new way to explore our product features
  • An updated interactive map to find the closest available treatment centers
  • Clinical data on hyperthermia with links to abstracts
  • Clinical studies that used Pyrexar products

We hope you will take a moment and explore the website. Your feedback is important and appreciated.

Other program notes:

We will be exhibiting at this year's ASTRO in San Antonio October 21-23.  If you are planning to attend, please stop by booth #1942 and see some of our new products for 2019 on display.

wanfang site visit

Hyperthermia is reemerging on to the cancer treatment stage. There is growing acceptance of hyperthermia's role as a radiosensitizer, its effectiveness when used with chemotherapy, and maybe its most important role, in immunomodulation.

Pyrexar Medical receives requests to introduce our hyperthermia systems into new countries every month. In 2015, we were selling in 9 countries, three years later the count has grown to well over 36 countries. But the road is long from introduction to sale and is often drawn-out with regulatory filings, physician education, toward eventual acceptance. That is why we are so thankful for physicians like Dr. Gi-Ming Lai, Director of the Wan Fang Cancer Center, and his team at the Taipei Municipal Wan Fang Hospital, part of the Taipei Medical University in Taiwan.

The clinical data for hyperthermia, and specifically the BSD-2000 Deep Regional Hyperthermia system, is very impressive. But potential customers often want to see a device in a treatment environment to understand workflow and treatment planning. So when a new distributor from the region requested to visit a reference site, we reached out to our partner network and Linden Bioscience of Taiwan answered the call.

"Wan Fang is a well respected center in Taiwan, and Dr. Lai's experience with hyperthermia is unparalleled in the region" says Tainang Huang, president of Linden Bioscience. "They have a well-outfitted radiation oncology department and a strong team in medical oncology under Dr. Lai's direction".  Wan Fang was the first JCI accredited hospital in Taiwan. The 730 bed facility has more than 350 full-time physicians, and over 2000 additional staff members. Because it is affiliated with Taipei Medical University, many doctors in training from the university complete internships at Wan Fang.

We believe with solid partnerships and a willingness to share knowledge, hyperthermia will continue to grow and serve cancer patients around the globe.

 

ASTRO's 60th Annual Meeting is the premier radiation oncology scientific event in the world and draws more than 11,000 attendees each year. This years exhibits will be held October 21-23th at the at the Henry B. Gonzalez Convention Center in downtown San Antonio, Texas (USA). Look for us in booth #1942.

ASTRO 2018 floorplan

We look forward to seeing you at the show. For more information visit the ASTRO website.

 


Pyrexar has signed with Kamol Sukosol Electric Company (KEC) to distribute Pyrexar's line of hyperthermia systems in Thailand. For over twenty years KEC has been supplying hospitals and clinics around the country with machinery vital in the fight against cancer. Their talented and well-trained sales and service group have started the process of introducing radiative phased array hyperthermia to their customers. Please join us in welcoming KEC to the Pyrexar family. We are fortunate to have such an excellent organization on our team. 

We were in Thailand in June to meet with Daranee Clapp, Executive VP of KEC, and her team to pitch the Pyrexar hyperthermia solution to several Bangkok area hospitals.  Below are a few photos of our visit.

THAI slideshow key


Kamol Sukosol Electric Company Background

KEC traces its roots back to 1939 when its president, Mr Kamol Sukosol, started the trading business with a shipment of twelve G.E. radio sets from the United States. Before too long the company grew to have 22 showrooms in Bangkok and its surrounding provinces. Less than a decade later, the company become G.E’s sole distributor in Thailand. With each passing year, new product lines were added and KEC’s scope of activities spread from household appliances to electrical and engineering equipment, air conditioning, motor vehicles, manufacturing and, most importantly, healthcare.  The company has a fascinating success story. You can read more here.